Skip to main content
SpringerLink
Log in

Role of ERβ in Clinical Breast Cancer

  • Chapter
  • First Online:
Hormone Receptors in Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 147))

  • 947 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925–30.

    Google Scholar 

  2. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53.

    Article  PubMed  CAS  Google Scholar 

  3. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997;11:353–65.

    Article  PubMed  CAS  Google Scholar 

  4. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258–65.

    Article  PubMed  CAS  Google Scholar 

  5. Menasce LP, White GR, Harrison CJ, et al. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993;17:263–5.

    Article  PubMed  CAS  Google Scholar 

  6. Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 1999;59:1175–9.

    PubMed  CAS  Google Scholar 

  7. Tong D, Schuster E, Seifert M, et al. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat. 2002;71:249–55.

    Article  PubMed  CAS  Google Scholar 

  8. Iwao K, Miyoshi Y, Egawa C, et al. Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer. 2000;88:733–6.

    Article  PubMed  CAS  Google Scholar 

  9. Poola I, Abraham J, Baldwin K, et al. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 2005;27:227–38.

    Article  PubMed  CAS  Google Scholar 

  10. Chu KC, Lamar CA, Freeman HP. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer 2003;97:2853–60.

    Article  PubMed  Google Scholar 

  11. Ogawa S, Inoue S, Watanabe T, et al. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998;243:122–6.

    Article  PubMed  CAS  Google Scholar 

  12. Wilkinson HA, Dahllund J, Liu H, et al. Identification and characterization of a functionally distinct form of human estrogen receptor beta. Endocrinology 2002;143:1558–61.

    Article  PubMed  CAS  Google Scholar 

  13. Xu L, Pan-Hammarstrom Q, Forsti A, et al. Human estrogen receptor β 548 is not a common variant in three distinct populations. Endocrinology 2003;144:3541–6.

    Article  PubMed  CAS  Google Scholar 

  14. Peng B, Lu B, Leygue E, Murphy LC. Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol. 2003;30:13–29.

    Article  PubMed  CAS  Google Scholar 

  15. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999;18:4608–18.

    Article  PubMed  CAS  Google Scholar 

  16. Klinge CM. Estrogen receptor interactions with co-activators and co-repressors. Steroids 2000;65: 227–51.

    Article  PubMed  CAS  Google Scholar 

  17. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998;247:75–8.

    Article  PubMed  CAS  Google Scholar 

  18. Paech K, Webb P, Kuiper GGJM, et al. Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites. Science 1997;277:1508–10.

    Article  PubMed  CAS  Google Scholar 

  19. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics. 2004;4:19–28.

    Article  PubMed  CAS  Google Scholar 

  20. Lazennec G, Bresson D, Lucas A, et al. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120–30.

    Article  PubMed  CAS  Google Scholar 

  21. Murphy LC, Peng B, Lewis A, et al. Inducible upregulation of oestrogen receptor-β1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol. 2005;34:553–66.

    Article  PubMed  CAS  Google Scholar 

  22. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64:423–8.

    Article  PubMed  CAS  Google Scholar 

  23. Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. 2004;5:174–81.

    Article  PubMed  CAS  Google Scholar 

  24. Bardin A, Boulle N, Lazennec G, et al. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11:537–51.

    Article  PubMed  CAS  Google Scholar 

  25. Ogawa S, Inoue S, Watanabe T, et al. Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. . Nucleic Acids Res. 1998;26:3505–12.

    Article  PubMed  CAS  Google Scholar 

  26. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000;19:4970–8.

    Article  PubMed  CAS  Google Scholar 

  27. Chi A, Chen X, Chirala M, et al. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res. 2003;23:211–6.

    PubMed  CAS  Google Scholar 

  28. Girault I, Andrieu C, Tozlu S, et al. Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett. 2004;215:101–12.

    Article  PubMed  CAS  Google Scholar 

  29. Poola I, Abraham J, Baldwin K, et al . Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 2005;27:227–38.

    Article  PubMed  CAS  Google Scholar 

  30. Herynk MH, Fuqua SAW. Estrogen Receptor Mutations in Human Disease. Endocr Rev. 2004;25:869–98.

    Article  PubMed  CAS  Google Scholar 

  31. Poola I, Abraham J, Baldwin K. Identification of ten exon deleted ER[beta] mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α. FEBS Lett. 2002;516:133–38.

    Article  PubMed  CAS  Google Scholar 

  32. Poola I, Abraham J, Liu A. Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J Steroid Biochem Mol Biol. 2002;82:169–79.

    Article  PubMed  CAS  Google Scholar 

  33. Inoue S, Ogawa S, Horie K, et al. An Estrogen Receptor [beta] Isoform That Lacks Exon 5 Has Dominant Negative Activity on both ERα and ERβ. Biochem Biophys Res Commun. 2000;279:814–19.

    Article  PubMed  CAS  Google Scholar 

  34. Speirs V, Adams IP, Walton DS, et al. Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor β in Normal Human Mammary Gland. J Clin Endocrinol Metab. 2000;85:1601–05.

    Article  PubMed  CAS  Google Scholar 

  35. Speirs V, Skliris GP, Burdall SE, et al. Distinct expression patterns of ER α and ER β in normal human mammary gland. J Clin Pathol. 2002;55:371–4.

    PubMed  CAS  Google Scholar 

  36. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol. 2003;27:1502–12.

    Article  PubMed  Google Scholar 

  37. Shaaban AM, Speirs V. The estrogen receptors α, β, and βcx. Clin Cancer Res. 2005;11:8222;author reply 8222–3.

    Article  PubMed  Google Scholar 

  38. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145–55.

    Article  PubMed  CAS  Google Scholar 

  39. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol. 2005;56 Suppl 1:21–6.

    Google Scholar 

  40. Skliris GP, Parkes AT, Limer JL, et al . Evaluation of seven oestrogen receptor β antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002;197:155–62.

    Article  PubMed  CAS  Google Scholar 

  41. Weitsman GE, Skliris G, Ung K, et al. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat. 2006.

    Google Scholar 

  42. Carder PJ, Murphy C, Dervan P, et al. A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERβ in Archival Formalin-fixed Paraffin Embedded Human Breast Tissue. Breast Cancer Res Treat. 2005;92:287–293.

    Article  PubMed  Google Scholar 

  43. Iwase H, Zhang Z, Omoto Y, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol. 2003;52 Suppl 1:S34–8.

    Article  PubMed  Google Scholar 

  44. Jarvinen TA, Pelto-Huikko M, Holli K, et al. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156:29–35.

    Article  PubMed  CAS  Google Scholar 

  45. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001;32:113–8.

    Article  PubMed  CAS  Google Scholar 

  46. Skliris GP, Carder PJ, Lansdown MR, et al. Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling? Br J Cancer. 2001;84:1095–8.

    Article  PubMed  CAS  Google Scholar 

  47. Hopp TA, Weiss HL, Parra IS, et al. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10:7490–9.

    Article  PubMed  CAS  Google Scholar 

  48. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004;57:523–8.

    Article  PubMed  CAS  Google Scholar 

  49. Myers E, Fleming FJ, Crotty TB, et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer. 2004;91:1687–93.

    PubMed  CAS  Google Scholar 

  50. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett. 2001;163:207–12.

    Article  PubMed  CAS  Google Scholar 

  51. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, et al. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res. 2005;11:3170–4.

    Article  PubMed  CAS  Google Scholar 

  52. Iwao K, Miyoshi Y, Egawa C, et al, Quantitative analysis of estrogen receptor –α and –β messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer 2000;89:1732–38.

    Article  PubMed  CAS  Google Scholar 

  53. Omoto Y, Kobayashi S, Inoue S, et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer. 2002;38:380–6.

    Article  PubMed  CAS  Google Scholar 

  54. Park BW, Kim KS, Heo MK, et al. The changes of estrogen receptor-? variants expression in breast carcinogenesis: decrease of estrogen receptor-?2 expression is the key event in breast cancer development. J Surg. Oncol. 2006;93:504–10.

    Article  PubMed  CAS  Google Scholar 

  55. Murphy CE, Carder PJ, Lansdown MRJ, et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg. Oncol 2006;32:44–7.

    Article  PubMed  CAS  Google Scholar 

  56. Roger P, Sahla ME, Makela S, et al Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537–41.

    PubMed  CAS  Google Scholar 

  57. Skliris GP, Munot K, Bell SM, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201:213–20.

    Article  PubMed  CAS  Google Scholar 

  58. Rody A, Diallo R, Poremba C, et al. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep. 2004;12:695–9.

    PubMed  CAS  Google Scholar 

  59. Zhao C, Lam EW, Sunters A, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22:7600–6.

    Article  PubMed  CAS  Google Scholar 

  60. Shaaban AM, Jarvis C, Moore F, et al. Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol. 2005;29:1593–9.

    Article  PubMed  Google Scholar 

  61. Cappelletti V, Celio L, Bajetta E, et al. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer. 2004;11:761–70.

    Article  PubMed  CAS  Google Scholar 

  62. Knowlden JM, Gee JM, Robertson JF, et al A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer. 2000;89:209–12.

    Article  PubMed  CAS  Google Scholar 

  63. Davies MP, O'Neill PA, Innes H, et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol. 2004;33:773–82.

    Article  PubMed  CAS  Google Scholar 

  64. Murphy LC, Leygue E, Niu Y, et al Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer. 2002;87 1411–16.

    Article  PubMed  CAS  Google Scholar 

  65. Miller WR, Anderson TJ, Dixon JM, et al. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer. 2006;94:1333–8.

    Article  PubMed  CAS  Google Scholar 

  66. Saji S, Omoto Y, Shimizu C, et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res. 2002;62:4849–53.

    PubMed  CAS  Google Scholar 

  67. Palmieri C, Lam EW, Mansi J, et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res. 2004;10:2421–8.

    Article  PubMed  CAS  Google Scholar 

  68. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res. 2004;10:5769–76.

    Article  PubMed  CAS  Google Scholar 

  69. Chang HG, Kim SJ, Chung KW, et al. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med. 2005;83:132–9.

    Article  PubMed  CAS  Google Scholar 

  70. Murphy LC, Watson PH. Is oestrogen receptor- {beta} a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer. 2006;13:327–334.

    Article  PubMed  CAS  Google Scholar 

  71. Zhao C, Gustafsson JA, Dahlman-Wright K. Functional characterization of a novel variant of estrogen receptor beta identified in screening of DNA derived from African Americans. Pharmacogenet Genomics 2006;16:379–83.

    Article  PubMed  CAS  Google Scholar 

  72. Zheng SL, Zheng W, Chang BL, et al. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res. 2003;63:7624–9.

    PubMed  CAS  Google Scholar 

  73. Forsti A, Zhao C, Israelsson E, et al. Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat. 2003;79:409–13.

    Article  PubMed  Google Scholar 

  74. Maguire P, Margolin S, Skoglund J, et al. Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer. Breast Cancer Res Treat. 2005;94:145–52.

    Article  PubMed  CAS  Google Scholar 

  75. Georgopoulos NA, Adonakis GL, Fotopoulos A, et al. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer. Gynecol Endocrinol. 2006;22:185–9.

    Article  PubMed  CAS  Google Scholar 

  76. Hasegawa S, Miyoshi Y, Ikeda N, et al. Mutational analysis of estrogen receptor-beta gene in human breast cancers. Breast Cancer Res Treat. 2003;78:133–4.

    Article  PubMed  CAS  Google Scholar 

  77. Parker HD, Hanby AM, Bell SM, et al. Loss of heterozygosity at 14q does not correlate with estrogen receptor beta negative breast cancer. Breast Cancer Res Treat. 2005;94 (suppl 1):S245.

    Google Scholar 

  78. Nojima D, Li LC, Dharia A, et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-β gene in patients with prostate carcinoma. Cancer 2001;92:2076–2083.

    Article  PubMed  CAS  Google Scholar 

  79. Zhao C, Lam E, W-F., et al. Expression of estrogen receptor β isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22:7600–06.

    Article  PubMed  CAS  Google Scholar 

  80. Duong V, Licznar A, Margueron R, et al. ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2005;25:1799–06.

    Article  Google Scholar 

  81. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β. Endocrinology 1997;138:863–870.

    Article  PubMed  CAS  Google Scholar 

  82. Kelly WK, O'Connor OA, Krug LM, et al. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer. J Clin Oncol. 2005;23:3923–31.

    Article  PubMed  CAS  Google Scholar 

  83. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin Cancer Res. 2006.

    Google Scholar 

  84. Jordan V. Designer estrogens. Sci Am. 1998;279:60–7.

    Article  PubMed  CAS  Google Scholar 

  85. Yamamoto Y, Shibata J, Yonekura K, et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005;11:315–22.

    PubMed  CAS  Google Scholar 

  86. Schopfer U, Schoeffter P, Bischoff SF, et al. Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes. J Med Chem. 2002;45:1399–401.

    Article  PubMed  CAS  Google Scholar 

  87. Malamas MS, Manas ES, McDevitt RE, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004;47:5021–40.

    Article  PubMed  CAS  Google Scholar 

  88. De Angelis M, Stossi F, Carlson KA, et al. Indazole estrogens: highly selective ligands for the estrogen receptor beta. J Med Chem. 2005;48:1132–44.

    Article  PubMed  Google Scholar 

  89. Guerini V, Sau D, Scaccianoce E, et al. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res. 2005;65:5445–53.

    Article  PubMed  CAS  Google Scholar 

  90. Puddefoot JR, Barker S, Glover HR, et al. Non-competitive steroid inhibition of oestrogen receptor functions. Int J Cancer. 2002;101:17–22.

    Article  PubMed  CAS  Google Scholar 

  91. De Angelis M, Stossi F, Waibel M, et al. Isocoumarins as estrogen receptor beta selective ligands: isomers of isoflavone phytoestrogens and their metabolites. Bioorg Med Chem. 2005;13:6529–42.

    Article  PubMed  Google Scholar 

  92. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y et al. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene. 2003;22:5011–20.

    Article  PubMed  CAS  Google Scholar 

  93. Fuqua SAW, Schiff R, Parra I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumour parameters. Cancer Res. 2003;63: 2343–439.

    Google Scholar 

  94. Koda M, Sulkowski S, Kanczuga-Koda L, et al. Expression of ERalpha, ERbeta and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep. 2004;11: 753–59.

    PubMed  CAS  Google Scholar 

  95. Stefanou D, Batistatou A, Briasoulis E et al. Estrogen receptor beta (ERbeta) expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the Greek experience. Eur J Gynaecol Oncol. 2004;25:457–61.

    PubMed  CAS  Google Scholar 

  96. Jensen EV, Cheng G, Palmieri C et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA. 2001;98: 15197–02.

    Google Scholar 

  97. Jarzabek K, Koda M, Kozloski L et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer. 2005;41:2924–94.

    Article  PubMed  CAS  Google Scholar 

  98. Miyoshi Y, Taguchi T, Gustafsson JA, et al. Clinicopathological characteristics of estrogen receptor-beta-positive human breast cancers. Jpn J Cancer Res. 2001;92: 1057–61.

    PubMed  CAS  Google Scholar 

  99. Papadaki I, Mylona E, Giannopouloui I, et al. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology. 2005;46: 37–42.

    Article  PubMed  CAS  Google Scholar 

  100. O'Neill PA, Davies MP, Shaaban AM et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer. 2004;91:1694–102.

    PubMed  Google Scholar 

  101. Fleming FJ, Hill AD, McDermott EW et al. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab. 2004;89: 375–83.

    Article  PubMed  CAS  Google Scholar 

  102. Saunders PT, Millar MR, Williams K et al. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer. 2002;86: 250–56.

    Article  PubMed  CAS  Google Scholar 

  103. Choi Y, Pinto M. Estrogen receptor beta in breast cancer: associations between ERbeta, hormonal receptors, and other prognostic biomarkers. Appl Immunohistochem Mol Morphol. 2005;13:19–24.

    Article  PubMed  CAS  Google Scholar 

  104. Gruvberger-Saal SK, Bendahl PO, Saal LH et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res. 2007; 13: 1987–1994.

    Google Scholar 

  105. Novelli F, Milella M, Melucci E et al. A divergent role for estrogen receptor beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008; 10: R74.

    Google Scholar 

  106. Vinayagam R, Sibson DR, Holcombe C, et al. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer - a retrospective study. BMC Cancer. 2007; 7: 131–140.

    Google Scholar 

  107. Sugiura H, Toyama T, Hara Y et al. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol. 2007; 37: 820–828.

    Google Scholar 

  108. Skliris GP, Leygue E, Curtis-Snell L et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 2006; 95: 616–626.

    Google Scholar 

  109. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008; 26:3727–3734.

    Google Scholar 

  110. Shaaban AM, Green AR, Karthik S et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res. 2008; 14: 5228–5235.

    Google Scholar 

  111. Skliris GP, Leygue E, Watson PH et al. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol. 2008; 109: 1–10.

    Google Scholar 

Download references

Acknowledgments

We gratefully acknowledge Yorkshire Cancer Research, Breast Cancer Campaign, Breast Cancer Research Trust, Breast Cancer Research Action Group, Liz Dawn Breast Cancer Appeal and the Leeds Teaching Hospitals NHS Trust for supporting our ERβ research program.

Author information

Authors and Affiliations

  1. Section of Pathology and Tumor Biology, Leeds Institute of Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds, LS9 7TF, UK

    Valerie Speirs

Authors
  1. Valerie Speirs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abeer M. Shaaban
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valerie Speirs .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, U.S.A.

    Suzanne A. W. Fuqua

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Speirs, V., Shaaban, A.M. (2009). Role of ERβ in Clinical Breast Cancer. In: Fuqua, S. (eds) Hormone Receptors in Breast Cancer. Cancer Treatment and Research, vol 147. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09463-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-09463-2_2

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-09462-5

  • Online ISBN: 978-0-387-09463-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation